Hot Features
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-con... Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.055 | -4.91071428571 | 1.12 | 1.18 | 1.03 | 479652 | 1.11283935 | CS |
| 4 | -0.275 | -20.5223880597 | 1.34 | 1.4 | 1.03 | 391023 | 1.23087081 | CS |
| 12 | 0.035 | 3.39805825243 | 1.03 | 1.71 | 0.89735 | 709559 | 1.29436852 | CS |
| 26 | -0.005 | -0.467289719626 | 1.07 | 1.71 | 0.89735 | 519597 | 1.19497973 | CS |
| 52 | -0.385 | -26.5517241379 | 1.45 | 1.71 | 0.88 | 614325 | 1.16477447 | CS |
| 156 | 0.315 | 42 | 0.75 | 3.12 | 0.661 | 412204 | 1.39067619 | CS |
| 260 | -1.565 | -59.5057034221 | 2.63 | 4.96 | 0.45 | 382080 | 1.69512961 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.